Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction in Convalescent Period
NCT03176498Phase 2Suspended
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic umbilical cord mesenchymal stem cells in cerebral infarction (2 arms), sponsored by Sclnow Biotechnology Co., Ltd. Primary endpoint: Motor function analysis at 6 months. Planned start Dec 2026; status: suspended.
02
Drugs
allogeneic umbilical cord mesenchymal stem cells
03
Conditions
cerebral infarction
Beyond the preview
Go deeper on NCT03176498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176498.